Beat
Electrophysiology materially exceeded consensus as FARAPULSE adoption drove exceptional growth.
[AS-EXP-027]Boston Scientific
Q1 2025: Boston Scientific raised growth through a tariff shock, reinforcing the resilience premium.
ResultBeatGuidanceRaisedEnvironmentimproving
Investment snapshot
What happened and why it mattered
Raised
The company lifted 2025 organic growth by about two percentage points while absorbing roughly $200 million of tariff cost.
[AS-EXP-027]No clear inflection
The company lifted 2025 organic growth by about two percentage points while absorbing roughly $200 million of tariff cost.
[AS-EXP-027]Qualitative
The shares gained because peers were still quantifying tariffs while Boston Scientific protected both growth and earnings.
[AS-ME-083]Results versus expectations
The print and the three most important read-throughs
Electrophysiology materially exceeded consensus as FARAPULSE adoption drove exceptional growth.
- 1
Electrophysiology materially exceeded consensus as FARAPULSE adoption drove exceptional growth.
Guidance bridge
GuidanceRaisedLatest outlook and KPI implications
The company lifted 2025 organic growth by about two percentage points while absorbing roughly $200 million of tariff cost.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY25 organic sales growth | 10–12% | 12–14% | ~12% (Jefferies cons) | +200bps midpoint (11%→13%) | Updated | Broad-based cardiology strength + category-leadership execution |
| FY25 reported sales growth | 12.5–14.5% | 15–17% | 14.5% (TD Cowen) | +250bps midpoint (13.5%→16%) | Updated | Organic raise + lower FX headwind |
| FY25 adjusted EPS | $2.80–$2.87 | $2.87–$2.94 | $2.86 (Jefferies cons) | +$0.07 midpoint (~+2.5%) | Updated | Sales upside offsetting tariffs |
| FY25 FX headwind (top line) | ~100bps | ~50bps | — | -50bps (favorable) | Updated | Dollar weakened since Feb |
| FY25 M&A contribution | ~350bps | ~350bps | — | No change | Maintained | Closed-deal annualization |
| FY25 adjusted gross margin | Improve vs 2024 | Roughly in line with 2024 (~70.3%) | — | Lowered | Lowered | ~$200M tariff on COGS line |
Management signal — paraphrased
The company lifted 2025 organic growth by about two percentage points while absorbing roughly $200 million of tariff cost.
Implied cadence
The company lifted 2025 organic growth by about two percentage points while absorbing roughly $200 million of tariff cost.
Stock reaction
Why the shares moved
The shares gained because peers were still quantifying tariffs while Boston Scientific protected both growth and earnings.
- The shares gained because peers were still quantifying tariffs while Boston Scientific protected both growth and earnings.
Did the reaction persist?
[AS-ME-083]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentimprovingWhat management said about the operating backdrop
Boston Scientific raised growth through a tariff shock, reinforcing the resilience premium.
- Customer demandNot stated
Not separately stated
OutlookNot separately statedKPI implicationNot separately statedSynthesis · Medium confidence · AS-ME-083 - Regional / ChinaStable/mixed
China grew HSD% on a ~+40% comp; "China represents a plus $1 billion market" with big '26 EP impact
OutlookMid-teens China growth reiterated; VBP pressure on PI persistsKPI implicationNot separately statedChina 7–8% of revenue; largest tariff variable · Management interpretation confidence · [124]
- Procedure volumes "strong in Q1," some capacity-expansion conversationsConcomitant PFA+WATCHMAN a "win/win/win"; demand durable
Improving
OutlookUnderpins +18.2% organic beatKPI implicationNot separately statedManagement interpretation · High confidence · [119] - Channel / inventoryStable
Tariffs "capitalized in the inventory and recognized in the P&L over…finished goods inventory turns," so Q2 impact minimal
Outlook2H-loaded tariff timing driven by ~7-month inventory daysKPI implicationNot separately statedQ2 EPS protected; 2H EPS pressured · Disclosed fact confidence · [121] - Supply availabilityWorsening (localized)
"Experiencing some supply chain issues across some specific categories…impacting some back orders within urology"
OutlookExpected to improve but "a bit of a headwind for us in '25"KPI implicationNot separately statedUrology $633M (+4.4% org) missed $647M Street · Management interpretation confidence · [122]
- Competition (PFA/EP)Improving
Now #2 US AF-ablation player with >70% PFA segment share; "mass adoption to PFA usage, and we have a lot of momentum"
OutlookShare likely ceded as MDT Affera/JNJ Varipulse/ABT Volt ramp, but market growth offsetsKPI implicationNot separately statedEP $730M (+145% org); supports Cardiology beat · Management interpretation confidence · [117] - PricingStable/improving
FARAPULSE/WATCHMAN GM-accretive mix driving 71.5% adj GM (+170bps y/y); no adverse pricing shift called out
OutlookMix tailwind persists as single-use catheters grow shareKPI implicationNot separately statedAdj GM 71.5%; supports margin beat · Disclosed fact confidence · [118]
Evidence and confidence
Source map
The response is analytically usable but ends with a flattened citation list rather than the requested structured native source map.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗